KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Italian drugmaker Chiesi to buy KalVista for $1.9 billion
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 2,686 Shares of Stock
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,862 Shares
KalVista Pharmaceuticals (NASDAQ:KALV) CFO Brian Piekos Sells 1,862 Shares of Stock
KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 8.7% Higher Following Analyst Upgrade
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High Following Analyst Upgrade
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
Financial Survey: SCYNEXIS (NASDAQ:SCYX) and KalVista Pharmaceuticals (NASDAQ:KALV)
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion
KalVista Pharmaceuticals (NASDAQ:KALV) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) Financial Review
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade
Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Moderate Buy” from Brokerages
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect?
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug
Stock Market Today: Nasdaq 100, S&P 500 Futures Gain As Investors Await December Jobs Report— General Motors, Offerpad, Tilray In Focus
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of “Moderate Buy” by Analysts
KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript
Investors Buy Large Volume of KalVista Pharmaceuticals Put Options (NASDAQ:KALV)
KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting